Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

ClinicalTrials.gov ID: NCT03691493

Public ClinicalTrials.gov record NCT03691493. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well radiation therapy given with standard care palbociclib and hormone therapy work in treating patients with breast cancer that has spread from one part of the body to the bone. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Antihormone therapy, such as fulvestrant, letrozole, anastrozole, exemestane, or tamoxifen, may lessen the amount of estrogen made by the body. Giving radiation therapy, palbociclib, and hormone therapy may work better in treating breast cancer patients with bone metastasis.

Study identification

NCT ID: NCT03691493
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Emory University; Other
Enrollment: 36 participants

Conditions and interventions

Conditions

Interventions

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 7, 2019
Primary completion: Oct 12, 2022
Completion: Oct 12, 2022
Last update posted: Feb 16, 2025

2019 – 2022

United States locations

U.S. sites: 10
U.S. states: 2
U.S. cities: 5

Facility	City	State	ZIP	Site status
Grady Health System	Atlanta	Georgia	30303	—
Emory University Hospital Midtown	Atlanta	Georgia	30308	—
Piedmont Hospital	Atlanta	Georgia	30309	—
Emory University Hospital/Winship Cancer Institute	Atlanta	Georgia	30322	—
Emory Saint Joseph's Hospital	Atlanta	Georgia	30342	—
Northside Hospital	Atlanta	Georgia	30342	—
Augusta University Medical Center	Augusta	Georgia	30912	—
John B. Amos Cancer Center	Columbus	Georgia	31904	—
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah	Georgia	31405	—
Maine Medical Center-Bramhall Campus	Portland	Maine	04102	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03691493, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 16, 2025 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03691493 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →